secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004581
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones
--------------------------------------------------------------------------------

- Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.
- CAN-2409 BLA submission for prostate cancer on track for Q4 2026; phase 3 data to be presented at upcoming scientific conference.
- Updated overall survival data for CAN-2409 in pancreatic and lung cancer expected Q1 2025.
- Phase 1b CAN-3110 overall survival data in recurrent high-grade glioma expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/0000950170-25-004581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer